CASI Pharmaceuticals Inc

NEW
OTCPK:CASIF (China)  
$ 0.13 (0%) 07:08 PM EST
At Loss
Market Cap:
$ 2.67M
Enterprise V:
$ 24.53M
Volume:
0
Avg Vol (2M):
13.22K
Trade In:
Volume:
0
At Loss
Avg Vol (2M):
13.22K

Business Description

Description
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
Name Current Vs Industry Vs History
Cash-To-Debt
0.21
Equity-to-Asset
-1.45
Debt-to-Equity
-0.74
Debt-to-EBITDA
-0.61
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
-47.48
Distress
Grey
Safe
Beneish M-Score
-11.99
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
44.36
9-Day RSI
47.55
14-Day RSI
48.45
3-1 Month Momentum %
-5.89
6-1 Month Momentum %
-86.01
12-1 Month Momentum %
-91.5

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.27
Quick Ratio
0.24
Cash Ratio
0.11
Days Inventory
116.75
Days Sales Outstanding
123.39
Days Payable
43.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-15.2
Shareholder Yield %
-199.91
Name Current Vs Industry Vs History
Gross Margin %
48.65
Operating Margin %
-206.84
Net Margin %
-232
EBITDA Margin %
-217.42
FCF Margin %
-100.34
OCF Margin %
-100.2
ROA %
-136.66
ROIC %
-124.3
3-Year ROIIC %
-173.2
ROC (Joel Greenblatt) %
-382.71
Moat Score
2
Tariff Resilience Score
5

Financials (Next Earnings Date:2026-07-01 Est.)

CASIF's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:CASIF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

CASI Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 20.712
EPS (TTM) ($) -2.58
Beta 2.2309
3-Year Sharpe Ratio -0.29
3-Year Sortino Ratio -0.42
Volatility % 143.49
14-Day RSI 48.45
14-Day ATR ($) 0.045122
20-Day SMA ($) 0.133244
12-1 Month Momentum % -91.5
52-Week Range ($) 0.05 - 3.09
Shares Outstanding (Mil) 20.56

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CASI Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

CASI Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price ($)
Third quarter earnings results for 2026 2026-11-13 In 140 days
Second quarter earnings results for 2026 2026-08-28 In 63 days
First quarter earnings results for 2026 2026-07-01 In 5 days
General meeting for 2025 2026-07-01 In 5 days
Annual report for 2025 2026-05-15 0.14 (-17.65%)
Third quarter earnings results for 2025 2025-11-14 1.34 (-5.99%)
Guggenheim Healthcare Innovation Conference 2025-11-12 09:30 1.38 (+2.99%)
H.C. Wainwright 27th Annual Global Investment Conference 2025-09-08 10:00 2.34 (+5.41%)
Guidance call for 2025 2025-09-03 11:30 2.30 (+3.60%)
Second quarter earnings results for 2025 2025-08-29 2.44 (+11.42%)
Show
Entries

CASI Pharmaceuticals Inc Frequently Asked Questions

What is CASI Pharmaceuticals Inc(CASIF)'s stock price today?
The current price of CASIF is $0.13. The 52 week high of CASIF is $3.09 and 52 week low is $0.05.
When is next earnings date of CASI Pharmaceuticals Inc(CASIF)?
The next earnings date of CASI Pharmaceuticals Inc(CASIF) is 2026-07-01 Est..
Does CASI Pharmaceuticals Inc(CASIF) pay dividends? If so, how much?
CASI Pharmaceuticals Inc(CASIF) does not pay dividend.

Guru Commentaries on OTCPK:CASIF

No articles.

Articles on CASI Pharmaceuticals Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1